Molecular imaging biomarkers as a tool in development of novel medicines

Trends on the Role of PET in Drug Development

Volumn , Issue , 2012, Pages 33-48

  Maguire, R Paul ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84986570003     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1142/9789814317740_0003     Document Type: Chapter

References (13)

1. Biomarker Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95.
2. Brix G, Zaers J, et al. Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association. J Nucl Med 1997; 38: 1614-1623.
3. Eisenhauer EA, Therasse P, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
4. Fisher LD, van Belle G. Biostatistics: A Methodology for the Health Sciences. New York: Wiley, 1993.
5. Hietala J, Nagren K, et al. Measurement of striatal D2 dopamine receptor density and affinity with [11C]-raclopride in vivo: a test-retest analysis. J Cereb Blood Flow Metab 1999; 19: 210-217.
6. Honey G, Bullmore E. Human pharmacological MRI. Trends Pharmacol Sci 2004; 25: 366-374.
7. Innis RB, Cunningham VJ, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007; 27: 1533-1539.
8. Ma Y, Eidelberg D. Functional imaging of cerebral blood flow and glucose metabolism in Parkinson’s disease and Huntington’s disease. Mol Imaging Biol 2007; 9: 223-233.
9. Mueller SG, Weiner MW, et al. Ways toward an early diagnosis in Alzheimer’s disease: the Alzheimer’s disease neuroimaging initiative (ADNI). Alzheimers Dement 2005; 1: 55-66.
10. Seminowicz DA, Mayberg HS, et al. Limbic-frontal circuitry in major depression: a path modeling metanalysis. Neuroimage 2004; 22: 409-418.
11. Talbot PS, Laruelle M. The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development. Eur Neuropsychopharmacol 2002; 12: 503-511.
12. Uppoor RS, Mummaneni P, et al. The use of imaging in the early development of neuropharmacological drugs: a survey of approved NDAs. Clin Pharmacol Ther 2008; 84: 69-74.
13. Verbruggen A, Coenen HH, et al. Guideline to regulations for radiopharmaceuticals in early phase clinical trials in the EU. Eur J Nucl Med Mol I 2008;35:2144-2151.